

Review Article

Prolonged Survival in a Non-Small Cell Lung Cancer with Brain Metastasis Treated with a Brain Mass Evacuation and Gefitinib

Mardiah Suci Hardianti, Johan Kurnianda

Division of Hematology and Medical Oncology, Department of Internal Medicine
Sardjito General Hospital/ Universitas Gadjah Mada, Yogyakarta

INTRODUCTION

The incidence of brain metastasis (BM) is reported to be increase about 20-40% over the last few years in patients with non-small-cell lung cancer (NSCLC).¹ The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in NSCLC patients with BM, especially those harboring EGFR mutations have been reported.

CASE REPORT

A 56-year-old woman with the initial major complaint of persistent and progressive headache within the last 4 months. Within the last 1 year before she sometimes complained of mild to moderate headache that still allowed her to work. She had sought for medication to several private hospitals before then referred to our hospital. A head computed tomography (CT)-scan confirmed multiple lesion in the frontal area (January 29 2013) (Figure 1). She was admitted into our hospital with worsening symptoms of consciousness and unable to communicate either passively or actively since the last days before hospitalization. Other imaging finding was a suspected mass in

the lung eventhough the patient had never complained for any respiratory problems (Figure 2)



Figure 1. A head computed tomography (CT)-scan confirmed multiple lesion in the frontal area

Her initial condition urged a salvage craniotomy for mass evacuation on February 6th 2013. Pathology examination revealed in a metastatic adenocarcinoma. She was discharged a week after the operation in a stable condition. She returned to Sardjito hospital in May 2013 with the other complaint of dyspneu and cough, after visiting a private hospital and had a thorax-CT which confirmed a lung mass of the medial lobe of the left lung




Figure 2a and b. Suspected lung mass of the left medial lobe (2.5x2cm)

(Figure 3). An ultrasound guided fine needle aspiration confirmed a diagnosis of Non Small Cell Carcinoma. The EGFR mutation analysis from the fine needle aspiration revealed a deletion at exon 19.




Figure 3. Lung mass of the left medial lobe (3.3x2cm)

She also felt that the headache got progressive in the last one month. Evaluation of head CT Scan showed multiple brain metastasis of the frontal area (Figure 4).

The administration of EGFR-TKI (Gefitinib) was started in May 23 2013. The




Figure 4. Multiple brain metastasis in the frontal area. Shifting of the midline to the right of 1 cm

following imaging for evaluation showed improvements of the brain and lung (Figure 5a and b).

The patient kept on consuming Gefitinib for 16 months (May 2013- September 2014). During this period the patient mostly had a good cognitive function, and good daily functional and social life. However, her husband informed that she recently sometimes complained of slight headache and forgetfulness. Head MSCT was done with result of multiple brain metastasis of the left frontal lobe with midline




Figure 5a. Improvement of the perifocal edema and lesion in the right frontal area (when compared to the result in September 2013), 5b. Two months after routine Gefitinib administration.




Figure 6. Multiple brain metastasis of the left frontal lobe with midline shifting to the right



Figure 7. Compared with September 2013: stable disease for partial response (d 0.7cm)

shifting to the right (Figure 6). Thorax MSCT resulted in stable disease for partial response (d 0.7cm) as compared to the result in September 2013 (Figure 7).

DISCUSSION

Non-small-cell lung cancer (NSCLC) is still the leading cause of cancer-related death worldwide, mainly due to its high incidence and late diagnosis. The 20–40% increase in the incidence of brain metastasis (BM) in NSCLC patients reported over the last few years is largely the result of advances in neuroimaging and prolonged survival achieved using new treatments.¹ BM has long been a major issue in clinical practice, since its symptoms lead to a significant impairment of quality of life and a rapid decline in the patient's clinical condition. If untreated, the prognosis of BM patients is poor, with a median survival of 1–2 months.¹

In this case the initial complaints of the patient was persistent headache which gradually progressed leading to lack of consciousness and motoric aphasia. The symptoms of mild to moderate headache had started approximately

from one year before getting worsened in the last 4 months.

Several treatments for BM include whole-brain radiation therapy (WBRT), long considered the cornerstone of treatment, is effective in achieving local disease control and a survival prolongation of 4–6 months, with an improvement or, at least, a stabilization in symptoms, but it is frequently burdened with significant comorbidities and side effects. In the presence of one to three brain lesions, the treatment of choice may be gamma knife, radiosurgery or surgical removal, which is known to prolong survival.²

In this case a salvage craniotomy for mass evacuation was done due to severe clinical symptoms of lack of consciousness and motoric aphasia.

The efficacy of chemotherapy in the treatment of patients with BM is limited, with data reported in various studies showing response rates ranging from 15 to 50%. Interestingly, following chemotherapy for BM, the response rates achieved are comparable with those obtained in systemic disease. Nonetheless, the median survival remains poor, ranging from 4 to 6 months.³

The blood–brain barrier (BBB) is an anatomic structure consisting of endothelial vessel cells, astrocytes and pericytes with tight junctions (TJs) and a number of carrier proteins which controls and limits the passage of molecules to the brain. In the presence of an intact BBB, only small lipophilic molecules (molecular weight [MW] <400 Da) can cross the BBB by diffusion, while the passage of other molecules is regulated by the carrier proteins. The loss of TJs in the tumor vascular system in macroscopic intracranial lesion does not necessarily incur the loss of other biological BBB components, such as

detoxification and drug resistance mechanisms, which may remain effective and compromise drug concentrations in BM.⁴

Epidermal growth factor receptor (EGFR)-dependent pathway plays an important role in the development and progression of human epithelial cancers, including NSCLC. EGFR is expressed on the cell surface of a substantial percentage of NSCLCs. Activation of the EGFR pathway is able to promote tumor growth and progression, stimulating cancer cell proliferation, production of angiogenic factors, invasion and metastasis, and inhibiting apoptosis.⁵ EGFR works through two different downstream signaling pathways, which are activated by the phosphorylation of the ATP-binding domain of the receptor: the MAPK cascade, which activates different genes linked to cell proliferation and survival; and the PI3K–AKT cascade, in which phosphorylated AKT inactivates proapoptotic proteins. TKIs inhibit the phosphorylation and tyrosine kinase activity of the intracellular domain of EGFR through competitive binding to this site, thus preventing the activation of downstream signaling.⁶ In general, activating EGFR mutations are more commonly observed in patients with adenocarcinomas and no prior history of smoking, as well as in females and those of Asian descent.

Initial studies with the EGFR tyrosine kinase inhibitors (TKIs) demonstrated biologic and clinical activity in only a relatively limited subset of lung cancers. The highest response rates to these TKIs were seen in patients with somatic mutations within the EGFR-TK domain, particularly exon 19 deletion, exon 21 L858R, and exon 18 G719X. These activating EGFR mutations are associated with high response rates to EGFR tyrosine kinase inhibitor (TKI) therapy, with combined results from 21 studies from 2004 to 2006 showing

responses in 210 of 268 patients (78%). These response rates observed in patients with EGFR-mutant tumors receiving TKIs were much higher than what had been described in patients treated with standard platinum-doublet chemotherapy.⁷ By contrast, the exon 20 T790M mutation is associated with acquired resistance to TKI therapy.⁸

In this patient the result of EGFR mutation analysis from the fine needle aspiration revealed a deletion at exon 19 suggesting the administration of Gefitinib.

Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. All drug-resistant tumors retained their original activating EGFR mutations, and some acquired known mechanisms of resistance including the EGFR T790M mutation or MET gene amplification. Some resistant cancers showed unexpected genetic changes including EGFR amplification and mutations in the PIK3CA gene, whereas others underwent a pronounced epithelial-to-mesenchymal transition.⁹

In this case, the underlying cause of the progression was not yet defined. Nonetheless any molecular changes is possible. Further molecular analysis should be done not only to define the mechanism of resistance but also to determine further treatment.

REFERENCES

1. Wen PY, MB P, Loeffler J. Metastatic Brain Cancer. Wen PY, MB P, Loeffler J (Eds). Lippincott Williams and Wilkins, PA, USA, 1999.
2. Gaspar LE, Mehta MP, Patchell RA et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J. Neurooncol* . 2010. 96(1), 17–32.
3. Bartolotti M, Franceschi E, Brandes AA. EGF Receptor Tyrosine Kinase Inhibitors in the Treatment of Brain Metastases From Non-small-cell Lung Cancer. *Expert Rev Anticancer Ther* . 2012. 12(11):1429-1435.
4. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. *J. Clin. Oncol* . 2007. 25(16), 2295–2305.
5. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. *J Clin Oncol* . 2012 Aug 20;30(24):3002-11
6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A et al. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. *N Engl J Med* . 2010;362:2380-8.
7. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. *J Clin Oncol* . 2007 Feb 10. 25(5):587-95.
8. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* . 2005 Mar. 2(3):e73.
9. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB et al. *Sci Transl Med* . 2011 March 23; 3(75): 75ra26. doi:10.1126/scitranslmed.3002003.